Overview

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Status:
RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Collaborator:

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Treatments:

Gemcitabine
lenvatinib
Oxaliplatin